Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor

被引：9

作者：

Chong, Kah-Meng ^{[1
]}

Yang, Ching-Yao ^{[2
]}

Lin, Chien-Chin ^{[3
,4
,5
]}

Lien, Wan-Ching ^{[1
]}

机构：

[1] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Emergency Med, Coll Med, 7 ZhongShan South Rd, Taipei 100, Taiwan

[2] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Taipei, Taiwan

[3] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol,Coll Med, Taipei, Taiwan

[4] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Lab Med, Coll Med, Taipei, Taiwan

[5] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan

来源：

AMERICAN JOURNAL OF EMERGENCY MEDICINE | 2022年 / 56卷

关键词：

COVID-19; Moderna vaccine; mRNA-based vaccine; Immune thrombocytopenia; Immune checkpoint inhibitors;

D O I：

10.1016/j.ajem.2022.03.030

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1273 (Moderna) COVID-19 vaccine in an Asian woman with a history of refractory lung adenocarcinoma treated with durvalumab, an immune checkpoint inhibitor. Treatment with platelet transfusion (12 units) and oral prednisolone (1 mg/kg per day) significantly improved her hemoptysis with thrombocytopenia. To the best of our knowledge, this is the first case of ITP following Moderna inoculation among Asians. This study highlights a potential adverse effect of mRNA-based COVID-19 vaccines in cancer patients receiving immune checkpoint inhibitors. (C) 2022 Elsevier Inc. All rights reserved.

引用

页码：395.e1 / 395.e3

页数：3

共 24 条

[1]

AstraZeneca Pharmaceuticals LP, 2022, IMFINZI DURV

[2]

Bristol-Myers Squibb Company, 2022, YERVOY IP

[3]

Bristol-Myers Squibb Company, 2022, OPDIVO NIV

[4] Vaccine administration and the development of immune thrombocytopenic purpura in children [J].

Cecinati, Valerio ;

Principi, Nicola ;

Brescia, Letizia ;

Giordano, Paola ;

Esposito, Susanna .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (05) :1158-1162

[5] Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use [J].

Dougherty, Sean C. ;

Lynch, Alia C. ;

Hall, Richard D. .

CLINICAL CASE REPORTS, 2021, 9 (06)

[6] Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination [J].

Fueyo-Rodriguez, Omar ;

Valente-Acosta, Benjamin ;

Jimenez-Soto, Rodolfo ;

Neme-Yunes, Yvette ;

Ignacio Inclan-Alarcon, Sergio ;

Trejo-Gonzalez, Roxana ;

Angel Garcia-Salcido, Miguel .

BMJ CASE REPORTS, 2021, 14 (05)

[7]

Ganzel C, 2021, ISR MED ASSOC J, V23, P341

[8] Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine [J].

Helms, Jackie M. ;

Ansteatt, Kristin T. ;

Roberts, Jonathan C. ;

Kamatam, Sravani ;

Foong, Kap Sum ;

Labayog, Jo-mel S. ;

Tarantino, Michael D. .

JOURNAL OF BLOOD MEDICINE, 2021, 12 :221-224

[9] Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients [J].

Huang, Yiqing ;

Soon, Yu Yang ;

Aminkeng, Folefac ;

Tay, Sen Hee ;

Ang, Yvonne ;

Kee, Adrian C. L. ;

Goh, Boon Cher ;

Wong, Alvin S. C. ;

Soo, Ross A. .

INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) :636-644

[10] Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine [J].

Julian, Jeffrey A. ;

Mathern, Douglas R. ;

Fernando, Dinali .

ANNALS OF EMERGENCY MEDICINE, 2021, 77 (06) :654-656

← 1 2 3 →